FREQUENCY OF HYPERPARATHYROIDISM IN ADULT CHRONIC HEMODIALYSIS PATIENTS

A KHAN; N ANWAR; I MIRZA; T RASHID; N INAYATULLAH

doi:10.54112/pjicm.v5i02.103

Authors

A KHAN Department of Nephrology and Renal Transplant, Rehman Medical Institute Peshawar, Pakistan
N ANWAR Department of Nephrology and Renal Transplant, Rehman Medical Institute Peshawar, Pakistan
I MIRZA Department of Nephrology and Renal Transplant, Rehman Medical Institute Peshawar, Pakistan
T RASHID Department of Nephrology and Renal Transplant, Rehman Medical Institute Peshawar, Pakistan
N INAYATULLAH Department of Nephrology and Renal Transplant, Rehman Medical Institute Peshawar, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.103

Keywords:

Secondary Hyperparathyroidism, Chronic Hemodialysis, Parathyroid Hormone, Calcium, Phosphate

Abstract

Background: Secondary hyperparathyroidism (SHPT) is a frequent and significant complication in patients undergoing long-term hemodialysis. It arises due to chronic disturbances in mineral metabolism and is associated with adverse outcomes including bone disease and cardiovascular complications. Objective: This study aimed to determine the frequency of secondary hyperparathyroidism among adult patients receiving chronic hemodialysis. Study Design: This was a cross-sectional study. Setting: The study was conducted in the Nephrology Department of Rehman Medical Institute, Peshawar, Pakistan. Duration of Study: The data collection occurred over a defined study period (18-September-2024 to 18-March-2025). Methods: A total of 136 adult patients on maintenance hemodialysis for at least 12 months were enrolled. Secondary hyperparathyroidism was defined by parathyroid hormone (PTH) levels exceeding 70 pg/mL, in conjunction with hypocalcemia (serum calcium <8.5 mg/dL) and vitamin D deficiency (25(OH)-vitamin D <30 ng/mL). Relevant demographic and clinical information including comorbidities such as hypertension and diabetes was recorded. Data were analyzed using SPSS, with descriptive statistics used for frequency and mean calculations. Results: The mean age of participants was 51.71 ± 15.84 years. Of the total patients, 73 (53.7%) were male and 63 (46.3%) were female. Hypertension was observed in 56 patients (41.2%), and diabetes in 59 patients (43.4%). Secondary hyperparathyroidism was present in 85 patients, representing a frequency of 62.5%. Conclusion: A high prevalence of secondary hyperparathyroidism was observed among adult chronic hemodialysis patients. These findings emphasize the need for routine screening and timely intervention to manage mineral and bone disorders in this population.

References

Cruz D, Bellomo R, Kellum JA, De Cal M, Ronco C. The future of extracorporeal support. Crit Care Med. 2008;36(4):S243–52. https://doi.org/10.1097/CCM.0b013e318168e4f6

Arasu R, Jegatheesan D, Sivakumaran Y. Overview of hemodialysis access and assessment. Can Fam Physician. 2022;68(8):577–82. https://doi.org/10.46747/cfp.6808577

Blankestijn PJ, Vernooij RW, Hockham C, Strippoli GF, Canaud B, Hegbrant J, et al. Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. N Engl J Med. 2023;389(8):700–9. https://doi.org/10.1056/NEJMoa2304820

Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–22. https://doi.org/10.2471/BLT.17.206441

Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82. https://doi.org/10.1016/S0140-6736(14)61601-9

White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008;86(3):229–37. https://doi.org/10.2471/BLT.07.041715

Kashgary A, Hassanein DE. Epidemiology and patient characteristics of chronic kidney disease in Saudi Arabia. Res Square. 2024;1(1):1–9. https://doi.org/10.21203/rs.3.rs-3830286/v1

Saudi Center for Organ Transplantation (SCOT). Dialysis in the Kingdom of Saudi Arabia. Saudi J Kidney Dis Transpl. 2018;29(4):1012–20.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. https://doi.org/10.1097/01.ASN.0000133041.27682.A2

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109. https://doi.org/10.2215/CJN.12941213

Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760–71. https://doi.org/10.1111/j.1523-1755.2005.67139.x

EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. https://doi.org/10.1056/NEJMoa1205624

Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) foreword. Kidney Int Suppl. 2017;7(1):1–59. https://doi.org/10.1016/j.kisu.2017.04.001

Bashir AM, Alici G, Wabari MM, Adani AA, Ahmed HM. Prevalence of secondary hyperparathyroidism in adult chronic hemodialysis patients in Somalia. Res Square. 2022;1(1):1–9. https://doi.org/10.21203/rs.3.rs-1746641/v3

Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25(4):595–602. https://doi.org/10.1081/JDI-120022551

Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011;18(1):28–41. https://doi.org/10.1053/j.ackd.2010.10.003